Overview of reported therapies for primary cutaneous B-cell lymphomas
| Therapy . | References . |
|---|---|
| First- and second-line therapies | |
| Local radiotherapy | 5,21,,,,,,,,,–31,40,45,50,52,,,,,,,,–61,80,81,87,102,,,,,–108 |
| Systemic multiagent chemotherapy | 21,25,28,–30,40,45,52,53,56,78,,–81,84,85,93,96,104,105,109 |
| Systemic rituximab (Mabthera) | 34,–36,38,68,,,,,,,,–77,88,,,–92 |
| Chorambucil (Leukeran) | 23,25,31,39,60,110 |
| Excision | 5,21,25,28,,,–32,53,–55,60,81,104,111 |
| Antibiotics | 29,31,45,,–48,112 |
| Radiochemotherapy | 28,45,52,54,–56,94,95,113 |
| Investigational therapies | |
| IFN-α intralesional | 33,46,62,–64,114,–116 |
| Rituximab intralesional | 34,36,37,65,–67 |
| Adenovirus-mediated IFN-γ gene transfer | 99,–101 |
| Anecdotal therapies | |
| Photodynamic therapy | 117,118 |
| Cisplatin intralesional | 119 |
| Mechlorethamine/ clobetasol | 120 |
| Topical imiquimod | 121,122 |
| Topical hexadecylphosphocholine | 123 |
| Therapy . | References . |
|---|---|
| First- and second-line therapies | |
| Local radiotherapy | 5,21,,,,,,,,,–31,40,45,50,52,,,,,,,,–61,80,81,87,102,,,,,–108 |
| Systemic multiagent chemotherapy | 21,25,28,–30,40,45,52,53,56,78,,–81,84,85,93,96,104,105,109 |
| Systemic rituximab (Mabthera) | 34,–36,38,68,,,,,,,,–77,88,,,–92 |
| Chorambucil (Leukeran) | 23,25,31,39,60,110 |
| Excision | 5,21,25,28,,,–32,53,–55,60,81,104,111 |
| Antibiotics | 29,31,45,,–48,112 |
| Radiochemotherapy | 28,45,52,54,–56,94,95,113 |
| Investigational therapies | |
| IFN-α intralesional | 33,46,62,–64,114,–116 |
| Rituximab intralesional | 34,36,37,65,–67 |
| Adenovirus-mediated IFN-γ gene transfer | 99,–101 |
| Anecdotal therapies | |
| Photodynamic therapy | 117,118 |
| Cisplatin intralesional | 119 |
| Mechlorethamine/ clobetasol | 120 |
| Topical imiquimod | 121,122 |
| Topical hexadecylphosphocholine | 123 |